Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes

<p>Table S8. Genes used for gene set analysis</p>

保存先:

書誌詳細
第一著者:	Sung-Eun Lee (14855067) (author)
その他の著者:	Feng Wang (14855070) (author), Maison Grefe (14855073) (author), Abel Trujillo-Ocampo (14855076) (author), Wilfredo Ruiz-Vasquez (14855079) (author), Koichi Takahashi (14855082) (author), Hussein A. Abbas (14855085) (author), Pamella Borges (14855088) (author), Dinler Amaral Antunes (14855091) (author), Gheath Al-Atrash (14855094) (author), Naval Daver (14855097) (author), Jeffrey J. Molldrem (14855100) (author), Andrew Futreal (14855103) (author), Guillermo Garcia-Manero (14855106) (author), Jin S. Im (14855109) (author)
出版事項:	2025
主題:	Cancer Tumor Biology Immuno-oncology Hematological Cancers Immunotherapy Checkpoint blockade Tumor Microenvironment Tumor microcirculation
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S2 from Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
著者:: Dong-Chun Hong (16374308)
出版事項: (2025)

Supplementary Table S1 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
著者:: Yibin Dai (16374331)
出版事項: (2025)

Supplementary Table S2 from Integrative Single-Cell and Bulk Transcriptomes Analyses Identify Intrinsic HNSCC Subtypes with Distinct Prognoses and Therapeutic Vulnerabilities
著者:: Yibin Dai (16374331)
出版事項: (2025)

Supplementary Figure S8 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
著者:: Christine Pich-Bavastro (16509238)
出版事項: (2025)

Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Supplementary Figure S7 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
著者:: Alessio Cortellini (11023993)
出版事項: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
著者:: Joseph Toker (15399882)
出版事項: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Figure S1 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S2 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S3 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S4 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S5 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S6 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Figure S7 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Table S1-S9 from BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
著者:: Xiaodong Shu (16721586)
出版事項: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
著者:: Arianna Draghi (15126339)
出版事項: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
著者:: Clare Vesely (505402)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_891r1sjsslbe9l768pkaopk37f